Merck just turned up the heat on cancer vaccines

New money, same big bet

Merck is leaning harder into personalized cancer vaccines, and that’s the kind of move that tells you management isn’t treating this like a side quest. The company is expanding its collaboration with Moderna around individualized neoantigen therapy — basically, a hyper-customized vaccine approach designed to help the immune system spot each patient’s tumor more precisely.

Why this matters

This isn’t just biotech hand-waving. Merck already has a blockbuster immune-oncology franchise with Keytruda, so pairing that powerhouse with an experimental vaccine platform gives it another swing at a huge market. The combo approach has shown promising early results in melanoma, and Merck clearly thinks the long game here could be enormous if the data keep cooperating.

Pfizer gets dragged back into the conversation

And yes, Pfizer investors should perk up too. Pfizer and BioNTech are chasing a similar personalized mRNA cancer strategy, so Merck’s bigger commitment is basically the industry saying: "the race is on, and everyone wants a lane." If these programs keep advancing, the winner could end up with a whole new oncology growth engine instead of just another line item in the pipeline.

Big picture

For now, this is more about positioning than payday. But in pharma, positioning is the appetizer before the blockbuster meal — and Merck just made it clear it wants seconds.